comprehensive -WSS

comprehensive

author：hotspot 2025-09-02 06:37:49 - browse：38232

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Pharmacists can make shortage drugs, but at what cost?

WSS

Why health workers in Gaza are injured or die at high rates

The explosion of genetic testing requires a new approach

Affirmative action in medical school literally saved lives

Guidelines to prevent youth baseball injuries need more muscle

Affirmative action in medical school literally saved lives

2023 STAT Wunderkinds: get to know the winners

knowledge

comprehensive

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Continuity nursing helped my family in our darkest PICU moments

Peter Hotez and the public health issue of online harassment

Duchenne breakthrough therapy leaves behind pioneering families

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: Michael J. Fox on progress in Parkinson's research

The cancer drug shortage isn’t new — and neither are the solutions

Eli Lilly expects to double planned employment in Boston center

knowledge

STAT Summit: Michael J. Fox on progress in Parkinson's research

STAT Readout Newsletter: Today's biggest biotech updates

Sports medicine is finally prioritizing gender equality

UnitedHealth’s board chair also owns a personal investment firm

Medicare reduced heart disease by changing how it pays doctors

New air purifier tech could be key to improving indoor air quality

focus

knowledge

entertainment

hotspot